Perioperative use of statins in noncardiac surgery

Background: Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) can significantly decrease cardiovascular mortality and morbidity, irrespective of the patients' cholesterol status. This paper reviews the effects of perioperative statin therapy in patients undergoing noncardiac surgery. Method: A systematic literature review was undertaken of all published literature on this subject using Medline and cross-referenced. All published relevant papers on the perioperative use of statins were used. Results: Perioperative statin therapy is associated with a lower perioperative morbidity and mortality in patients undergoing elective or emergency surgery. The effects are due to a combination of lipid-lowering and pleiotropic properties of statins. Conclusion: Ideally a large scale multi-centre randomized controlled trial of perioperative statin therapy should be performed but this may be difficult to conduct since there is already overwhelming evidence in the literature to suggest perioperative cardiovascular protective properties. Statins may still be under-prescribed in surgical patients. © 2008 Chan et al, publisher and licensee Dove Medical Press Ltd.published_or_final_versio

Effects of Intra-Operative Total Intravenous Anaesthesia with Propofol versus Inhalational Anaesthesia with Sevoflurane on Post-Operative Pain in Liver Surgery: A Retrospective Case-Control Study

published_or_final_versio

sPDZD2: a novel negative modulator of hedgehog signaling

Poster Presentation - Theme 3: Development & stem cellsPDZD2 is a multi-PDZ domain-containing protein of unknown function in early development. It is proteolytically cleaved to generate its secreted form, sPDZD2. Human PDZD2 is mapped to chromosome 5p13.2, which co-localizes with the disease-associated gene in a family of Brachydactyly Type A1 (BDA1) patients, suggesting involvement of PDZD2 in limb development. Hedgehog (Hh) is an important morphogen that dictates tissue patterning during embryonic development and recent studies showed that mutations in Indian Hedgehog (IHH) resulted in ...postprin

The role of cyclooxygenase 1 and 2 in fracture repair - implications for atrophic nonunion

Session - Clinical PerspectiveConference Theme: Bone Tissue EngineeringeCMVIII was dedicated to honour of Prof. Dr. med. D.Sc. (h.c.) Stephan M Perren a world-renowned research trauma surgeon for his endless work on bone research, teaching, advising, fostering ideas and mentoring of scientists.published_or_final_versio

Differential functions of cyclooxygenase 1 and 2 in bone repair

Conference Theme: Spinal Motion Segment: From Basic Science to Clinical ApplicationPosterspublished_or_final_versio

N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson's Disease

Oxidative stress is a key mediator in the development and progression of Parkinson’s disease (PD). The antioxidant N-acetylcysteine (NAC) has generated interest as a disease-modifying therapy for PD but is limited due to poor bioavailability, a short half-life, and limited access to the brain. The aim of this study was to formulate and utilise mitochondria-targeted nanocarriers for delivery of NAC alone and in combination with the iron chelator deferoxamine (DFO), and assess their ability to protect against oxidative stress in a cellular rotenone PD model. Pluronic F68 (P68) and dequalinium (DQA) nanocarriers were prepared by a modified thin-film hydration method. An MTT assay assessed cell viability and iron status was measured using a ferrozine assay and ferritin immunoassay. For oxidative stress, a modified cellular antioxidant activity assay and the thiobarbituric acid-reactive substances assay and mitochondrial hydroxyl assay were utilised. Overall, this study demonstrates, for the first time, successful formulation of NAC and NAC + DFO into P68 + DQA nanocarriers for neuronal delivery. The results indicate that NAC and NAC + DFO nanocarriers have the potential characteristics to access the brain and that 1000 μM P68 + DQA NAC exhibited the strongest ability to protect against reduced cell viability (p = 0.0001), increased iron (p = 0.0033) and oxidative stress (p ≤ 0.0003). These NAC nanocarriers therefore demonstrate significant potential to be transitioned for further preclinical testing for PD

Peri-operative administration of rectal diclofenac sodium. The effect on renal function in patients undergoing minor orthopaedic surgery

In a randomized, double-blind study, we administered placebo and diclofenac sodium 100 mg suppositories 1 h pre-operatively and on the first post-operative morning to 22 adult patients undergoing minor orthopaedic surgery. A standardized post-operative intravenous fluid regimen was instituted until oral fluids were tolerated. Renal function was assessed pre-operatively, and on the first and second post-operative days by the measurement of urine output, creatinine, urea, sodium, potassium and NAG (N-acetyl-b-D-glucosaminidase) levels and serum creatinine, urea, sodium and potassium concentrations. On the first postoperative day, the diclofenac group demonstrated a reduced urinary sodium excretion. On the second postoperative day, a reduced urinary NAG/creatinine ratio was observed in the diclofenac group when compared to placebo. We conclude that peri-operative administration of diclofenac causes changes in renal function consistent with prostaglandin inhibition on the first post-operative day but had no lasting adverse effects in this group of patients. Our results reinforce the need for caution when administering this drug in the context of pre-existing renal impairment.published_or_final_versio

The clinical longevity of 239 cantilever resin-bonded prostheses

published_or_final_versio